A case of selective IgG subclass deficiency with STAT3 mutation  by Ohnishi, Hidenori et al.
lable at ScienceDirect
Allergology International 65 (2016) 495e497Contents lists avaiAllergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i tLetter to the EditorA case of selective IgG subclass deﬁciency with STAT3 mutationTable 1
Immunological ﬁndings of the patient at the age of 12 years.
Patient Normal values
Blood cells (/ml)
Leukocytes 4000 3400e9200
Lymphocytes 1916 19.0e45.4
(%Leukocytes)
Neutrophils 1460 45.6e73.2
(%Leukocytes)
Monocytes 192 2.0e7.5
(%Leukocytes)
Eosinophils 412 0.6e8.4
(%Leukocytes)
Lymphocytes subsets (%)
CD3 82.4 56.0e84.0
CD4 47.6 31.0e52.0
CD8 26.3 18.0e35.0
CD19 7.4 6.0e23.0
NK (CD3, CD56þ, CD16þ) 19.9 3.0e22.0
Serum immunoglobulin levels
IgG (mg/dl) 1934 770e1700
IgA (mg/dl) 27 67e363
IgM (mg/dl) 257 86e343
IgE (U/ml) 740 0e170
IgG subclass (mg/dl)
IgG1 1450 438.3e1284.3
IgG2 28 190.7e587.1
IgG3 5 13.6e106.4
IgG4 4 3.0e122.4
Speciﬁc antibodies
EBV-VCA-IgG (FA) ND <10 folds
EBV-EBNA (FA) ND <10 folds
VZV-IgG (EIA) 0.6 <2.0
Rubella-IgG (EIA) 114 <2.0
Measles-IgG (EIA) 7.7 <2.0
Streptococcus pneumonia speciﬁc IgG2 (mg/ml) 0.4 <0.35
T cell function
Lymphocyte proliferation assay
No stimulus (cpm) 175
PHA (cpm) 147793
PHA (stimulation index) 844.5 101.6e2643.8
Con A (cpm) 72570
Con A (stimulation index) 414.7 74.7e1793.2
Complement factors
C3 (mg/dl) 111.5 65e135
C4 (mg/dl) 10.9 13e35
50% hemolytic complement activity (U/ml) 39.0 30.0e45.0Dear Editor,
Human immunoglobulin G (IgG) consists of four IgG subclasses
(IgG1, IgG2, IgG3, and IgG4), and selective IgG subclass deﬁciency
is one of the well-known primary antibody deﬁciency syndromes.1
Recently, class-switch recombination deﬁciency with mutations in
the postmeiotic segregation 2 gene (PMS2) or the mutS homolog 6
gene (MSH6) has been suggested as the etiology of a part of the selec-
tive IgG subclass and IgA deﬁciency,2 although the etiology and the
disease severity of selective IgG subclass deﬁciency varies. More
recently, a patient reportedwith an abnormality in the phosphatidy-
linositol 3-kinase/v-akt murine thymoma viral oncogene homolog
(PI3K/AKT) signaling pathway, speciﬁcally a mutation in the phos-
phatidylinositol 3-kinase catalytic delta polypeptide gene (PIK3CD),
also showed signs of IgG subclass deﬁciency.3 In contrast, hyperim-
munoglobulin E (hyper-IgE) syndrome (HIES), deﬁned as extremely
high serum levels of IgE, confers immunodeﬁciency against speciﬁc
pathogens, including pyogenic bacteria, and chronicmucocutaneous
candidiasis, and also includes features such as facial dysmorphism,
impaired shedding of deciduous teeth, osteopenia, craniosynostosis,
and hyperextensibility.4 The etiology of HIES is attributed to muta-
tions in ﬁve genes, STAT3, tyrosine kinase 2 (TYK2), dedicator of cyto-
kinesis 8 (DOCK8), serine peptidase inhibitor, Kazal type 5 (SPINK5),
and phosphoglucomutase 3 (PGM3).1 In general, patients with HIES
showhigh serum IgE levels, but not reduced serum IgG levels. In this
letter, we describe a patient with a pathogenic STAT3mutation, who
presented with selective IgG subclass deﬁciency.
The patient is a girl, now 12 years old, whose immunodeﬁ-
ciency was apparent at 3 years of age, when she suffered oral
candidiasis. At the age of four, she was frequently admitted to hos-
pital with episodes of bronchial pneumonia and measles. At the
age of ﬁve, she suffered a pulmonary abscess, and received immu-
noglobulin replacement therapy. She was admitted with a pro-
longed varicella infection at the age of eight. Recently, she has
suffered from sinusitis about once every 3 months. There has
been no life-threatening or severe infection. She has sufferedmod-
erate atopic dermatitis and acne like eczema (Supplementary
Fig. 1). However, there is no hyperextensibility, high palate,
retained primary teeth, scoliosis, or midline anomaly. Until now,
she has suffered a bone fracture with minor trauma twice. Her
clinical diagnostic score for HIES, previously deﬁned by the Na-
tional Institutes of Health (NIH) and 40 points or greater of this
score have a high probability for a STAT3 mutation, is 33 points.5
Her immunological parameters are shown in Table 1,
Supplementary Table 1 and Figure 1. She showed relatively lowerPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).serum IgE levels than typical HIES patients. Her total serum IgG
level was appropriate or mildly increased for her age, but her
IgG2 level was low, and her IgG3 and IgA levels were also slightly
low (Table 1). Her proportions of CD19þ, CD3þ, CD4þ, and CD8þNeutrophil function
Neutrophil sterilizing function (%) 99.5 70e100
Con A, concanavalin A; ND, not detected.
vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Lymphocyte subsets of the patient and age-matched control subjects. (A) Flow-cytometric analysis of memory B cells. The proportion of isotype-class-switched memory B
cells (CD20þ,CD27þ,IgD) was lower in the patient than in the control subjects (n ¼ 10; aged 10e17 years; mean ± SD ¼ 13.5 ± 7.0%). (B) Flow-cytometric analysis of Th17 cells. The
proportion of CD4þ,IL-17Aþ,IFN-g T-helper type 17 (Th17) cells, which were incubated with 25 ng/mL phorbol myristate acetate and 1 mg/mL ionomycin for 4 h, was lower in the
patient than in the control subjects (n ¼ 10; aged 10e17 years; mean ± SD ¼ 1.42 ± 0.50%). (C) IL-17A production levels in the patient and control subjects evaluated with enzyme-
linked immunosorbent assay. The production of IL-17A by the phytohemagglutinin-stimulated for 24 h PBMCs from the patient (5.87 ± 2.05 pg/mL) was signiﬁcantly lower than that
from cells of the control subjects (242.04 ± 62.56 pg/mL) (n ¼ 5; aged 10e16 years). The statistical signiﬁcance of differences between the patient and the control subjects was
analyzed with the ManneWhitney U test. P values < 0.05 were considered statistically signiﬁcant.
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switched memory B cells in the patient were lower than those of
the age-matched control subjects (Fig. 1A). The proportions of T
helper type 17 (Th17) cells and the production levels of IL-17A
were also signiﬁcantly lower in the patient than in the age-
matched control subjects (Fig. 1B, C). Finally, a heterozygous
missense mutation c.1145G > A (p. R382Q) was detected in the
STAT3 gene of the patient. This mutation has previously been re-
ported as a pathogenic mutation of HIES and occurs at one of the
hot spots in this gene.6 There was no mutation in the STAT1,
PMS2, MSH6 and PIK3CD genes.
Thus, we identiﬁed a Th17 cell deﬁciency in this patient with
selective IgG subclass deﬁciency. A deﬁciency in IL-17 signaling
is known to be the etiology of chronic candidiasis, caused by a mu-
tation in the STAT1, STAT3, DOCK8, AIRE, IL17RA, or IL17F gene.5,7
This patient had suffered mild candidiasis in infancy. However,
because her immunodeﬁciency symptoms were very mild, and
she was initially diagnosed with IgG subclass deﬁciency and rela-
tively low serum IgE levels, her Th17 cell deﬁciency had not been
considered. Interestingly, a recent French survey of HIES with a
STAT3 mutation reported that only one patient had low serum
IgG2 levels, although no detailed proﬁle of the patient was pro-
vided in that manuscript.4 Therefore, this seems to suggest thatthe IgG subclass deﬁciency is a possible phenotype caused by a
STAT3 mutation.
STAT3 is a signal transducer and a transcription factor for
various cytokines and growth factors. It consists of an amino-
terminal domain, a coiled-coil domain, a DNA-binding domain
(DBD), a linker domain, an SH2 domain, and a transactivation
domain. Most of the mutations in STAT3 causing HIES are located
in the DBD and SH2 domain.6 A recent report showed the various
phenotypes of HIES patients withmutations in the DBD like this pa-
tient.8 Although this article by Wolach et al. did not describe the
serum IgG subclass values, we consider that patients with low
NIH scores and not extremely high serum IgE levels may have an
IgG subclass deﬁciency.
The mechanism underlying the elevated serum IgE levels in
STAT3-deﬁcient HIES patients has not been clariﬁed. Avery et al.
demonstrated impaired IL-21-induced secretion of IgE and
enhanced IL-4-induced secretion of IgE from the naïve B cells of
STAT3-deﬁcient patients, and showed that their CD4þ T cells pro-
duced lower levels of IFN-g and IL-10 than those of normal sub-
jects.9 These results may explain the typical phenotype of HIES,
but above-mentioned untypical phenotypes cannot yet be
explained. On the other hand, it is known that HIES patients have
low proportions of memory B cells4 and the proportion of
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Consequently, this patient suffers a disorder of immunoglobulin
class-switching, which might be associated with not only low
IgG2 but also low IgA and relatively low IgE in this case. These re-
sults may indicate that an aspect of the common variable immune
deﬁciency like feature of STAT3 deﬁciency.10 Therefore, we specu-
late that other genetic factors and environmental factors associated
with the cytokine balance, including IL-4, IL-10, IL-21, and IFN-g, or
the differentiation of B cells, may occasionally affect immunoglob-
ulin class-switching in STAT3-deﬁcient patients.
In conclusion, the disease spectrum of HIES, especially STAT3
deﬁciency, varies greatly, and our ﬁndings may provide a clue to
the unknown etiology of some patients with selective IgG subclass
deﬁciency.Acknowledgments
This work was supported by Grants-in-Aid for Scientiﬁc
Research from the Ministry of Education, Culture, Sports, Science
and Technology of Japan (14467821) and by Health and Labour Sci-
ence Research Grants for Research on Intractable Diseases from the
Ministry of Health, Labour and Welfare of Japan (14427223 and
14427260).Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.alit.2016.05.004.
Conﬂict of interest
The authors have no conﬂict of interest to declare.
Hidenori Ohnishi a,*, Norio Kawamoto a, Hideo Kaneko b,
Kimiko Kasahara a, Osamu Ohara c, Zenichiro Kato a,d,
Toshiyuki Fukao a
a Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japanb Department of Clinical Research, Nagara Medical Center, Gifu, Japan
c Department of Technology Development, Kazusa DNA Research Institute, Kisarazu,
Japan
d Structural Medicine, The United Graduate School of Drug Discovery and Medical
Information Sciences, Gifu University, Gifu, Japan
* Corresponding author. Department of Pediatrics, Graduate School of Medicine,
Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.
E-mail address: ohnishih@gifu-u.ac.jp (H. Ohnishi).References
1. Picard C, Al-Herz W, Bousﬁha A, Casanova JL, Chatila T, Conley ME, et al. Pri-
mary immunodeﬁciency diseases: an update on the classiﬁcation from the In-
ternational Union of Immunological Societies Expert Committee for Primary
Immunodeﬁciency 2015. J Clin Immunol 2015;35:696e726.
2. Durandy A, Kracker S, Fischer A. Primary antibody deﬁciencies. Nat Rev Immu-
nol 2013;13:519e33.
3. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phos-
phoinositide 3-kinase delta gene mutation predisposes to respiratory infection
and airway damage. Science 2013;342:866e71.
4. ChandesrisMO,Melki I,NatividadA,PuelA, FieschiC,YunL, et al.Autosomaldomi-
nant STAT3 deﬁciency and hyper-IgE syndrome: molecular, cellular, and clinical
features from a French national survey.Medicine (Baltimore) 2012;91:e1e19.
5. Schimke LF, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M,
et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clin-
ical key ﬁndings to differentiate hyper-IgE syndromes from atopic dermatitis. J
Allergy Clin Immunol 2010;126:611e7.
6. Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO, et al. Muta-
tions in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin
Immunol 2010;125:424e32.
7. McDonald DR. TH17 deﬁciency in human disease. J Allergy Clin Immunol
2012;129:1429e35.
8. Wolach O, Kuijpers T, Ben-Ari J, Gavrieli R, Feinstein-Goren N, Alders M, et al.
Variable clinical expressivity of STAT3 mutation in hyperimmunoglobulin E
syndrome: genetic and clinical studies of six patients. J Clin Immunol
2014;34:163e70.
9. Avery DT, Ma CS, Bryant VL, Santner-Nanan B, Nanan R, Wong M, et al. STAT3 is
required for IL-21-induced secretion of IgE from human naive B cells. Blood
2008;112:1784e93.
10. Agematsu K, Futatani T, Hokibara S, Kobayashi N, Takamoto M, Tsukada S, et al.
Absence of memory B cells in patients with common variable immunodeﬁ-
ciency. Clin Immunol 2002;103:34e42.
Received 25 November 2015
Received in revised form 28 March 2016
Accepted 1 May 2016
Available online 11 June 2016
